- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Journey Medical: Rosazea-Medikament Emrosi treibt Wachstum an | 1 | Investing.com Deutsch | ||
| 13.08. | Journey Medical signals continued ASP gains in 2H 2026 as Emrosi reaches $8.1M and 38% high-quality coverage | 19 | Seeking Alpha | ||
| 12.08. | Journey Medical steigert Umsatz im zweiten Quartal 2026 und erreicht positives EBITDA | 1 | Investing.com Deutsch | ||
| 12.08. | Journey Medical übertrifft Prognosen für Q2 2026 - Aktie legt zu | 1 | Investing.com Deutsch | ||
| 12.08. | Journey Medical Non-GAAP EPS of $0.10, revenue of $18.5M beats by $0.13M | 2 | Seeking Alpha | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | 195 | GlobeNewswire (Europe) | Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi revenues were $8.1 million for the second quarter of 2026 Strong revenue... ► Artikel lesen | |
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 | 1 | GlobeNewswire (USA) | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 3 | Seeking Alpha | ||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 338 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,000 | -0,31 % | Pfizer-Aktie im Check am 18.09. (08:27 Uhr): Meine aktuelle Lageeinschätzung | ||
| GILEAD SCIENCES | 130,62 | -0,62 % | Dividendenbekanntmachungen (15.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKVA GROUP ASA NO0003097503 1 NOK 0,0927 EUR ALEXANDRIA GROUP OYJ FI4000153465 - 0,35 EUR ALTRIA GROUP INC US02209S1033 1,11 USD 0... ► Artikel lesen | |
| ELI LILLY | 1.003,60 | -0,02 % | 3,8-Milliarden-Dollar-Deal von Eli Lilly, 400 Patienten und jetzt die FDA: Warum Australiens Psychedelika-Vorsprung Emyria in den Fokus rückt | ||
| VERTEX PHARMACEUTICALS | 444,00 | -1,27 % | Olympic skier Lindsey Vonn joins up with Vertex for pain campaign | ||
| EYEPOINT | 3,460 | -0,57 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| NEKTAR THERAPEUTICS | 58,72 | -1,44 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,621 | -1,74 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 246,00 | 0,00 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 215,60 | +1,51 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences | Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy
Transaction strengthens Jazz's epilepsy pipeline... ► Artikel lesen | |
| UNITED THERAPEUTICS | 430,30 | -0,28 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| ROYALTY PHARMA | 50,70 | -1,25 % | Royalty Pharma plc: Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program | ||
| OPKO HEALTH | 1,390 | -2,11 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 58,05 | -1,01 % | BridgeBio Pharma auf Morgan Stanley Konferenz: Attruby als Wachstumstreiber | ||
| TG THERAPEUTICS | 50,000 | +1,63 % | Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics Stock |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-0,41 %) liegt der Kurs bei 7,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.